Comparative Pharmacology
Head-to-head clinical analysis: DIFICID versus FORBAXIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIFICID versus FORBAXIN.
DIFICID vs FORBAXIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fidaxomicin is a macrocyclic antibiotic that inhibits bacterial RNA polymerase, leading to RNA synthesis inhibition and cell death. It is bactericidal against Clostridioides difficile and has minimal systemic absorption.
FORBAXIN is a prodrug of the active moiety cefditoren, a cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
200 mg (tablet) orally twice daily for 10 days.
IV: 500 mg every 12 hours, infused over 30 minutes.
None Documented
None Documented
11.7 hours (terminal half-life in healthy subjects); supports twice-daily dosing.
8-12 hours; prolonged in renal impairment (up to 24 hours in severe cases)
Fecal (primarily as unchanged drug, ~44% of dose); renal (~1.6% unchanged, <1% as metabolites); biliary (minor).
Renal (60-70% unchanged), biliary/fecal (20-30%)
Category C
Category C
Antibiotic
Antibiotic